XORTX Therapeutics Inc. stocks have been trading up by 13.55 percent following highly positive news on its lead kidney therapy.
Click Here for a Millionaire's POV on Trading XRTX
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways Traders Should Watch
- Contract manufacturing of GMP oxypurinol and commercial XORLO tablets positions XRTX closer to the planned XRX-OXY-102 gout trial and a future NDA push.
- Clinical and commercial-scale Xorlo production supports the XRx-026 gout program after prior study data and FDA talks signaled a path forward.
- XORTX terminated a $2.5M IR and marketing deal, recovered the cash, postponed the campaign, and is voluntarily delisting from the TSX Venture Exchange while keeping Nasdaq.
- The company switched transfer agents and clarified $240,000 in finder’s fees tied to its April 2026 Vectus renal asset deal, while reiterating its late-stage kidney and gout pipeline.
Live Update At 12:32:19 EDT: On Friday, September 18, 2026 XORTX Therapeutics Inc. stock [NASDAQ: XRTX] is trending up by 13.55%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
XORTX Therapeutics Inc. is a classic high-risk biotech ticker in trading terms. XRTX has tiny revenue, heavy losses, and a story driven almost entirely by its kidney and gout pipeline. The numbers confirm that.
For the latest reported quarter ending 2026/06/30, XORTX posted total revenue of just $34,200 against total expenses of about $1.72M. That left XRTX with a net loss of roughly $1.69M and basic EPS of -$1.05. Profitability ratios are deeply negative, with return on equity near -99%, which screams “development-stage burn,” not steady cash machine.
On the balance sheet, XRTX shows about $994,000 in cash and total assets around $6.18M, supported by common stock of roughly $20.8M and only $680,000 in liabilities. A current ratio of 3.6 means XORTX can cover near-term bills, but free cash flow of about -$3.4M highlights the ongoing cash drain.
More Breaking News
- SYRE Stock Steadies As SPY003 Trial Data De-Risks IBD Pipeline
- ABAT Stock Draws Traders After Huge Revenue Jump And Lithium Win
- FHTX Stock Slides As Traders Focus On Cash Runway And Charts
- MARA Stock Drops As JPMorgan Slashes Price Target
For traders, that mix tells a simple story: XRTX lives and dies by capital raises and catalysts. No steady earnings floor. Every FDA update, trial headline, or financing move can swing the tape fast.
Why Traders Are Watching XRTX Now
XORTX Therapeutics has just moved its XRx-026 gout program from concept to execution mode, and that is why XRTX is back on radar screens. The company kicked off contract manufacturing of GMP oxypurinol drug substance and commercial-scale XORLO tablets. This is not a minor lab event. It’s the kind of de-risking step biotech traders look for before late-stage trials.
Those XORLO tablets are being lined up to supply the planned XRX-OXY-102 clinical trial. At the same time, XORTX is generating validation and stability data meant to support a future New Drug Application and potential FDA marketing approval. In plain English: XRTX is spending real money to prepare for the day it asks regulators to greenlight its gout drug.
XORTX also began clinical and commercial-scale manufacturing of Xorlo, its proprietary oxypurinol formulation, specifically to support that XRx-026 gout program and the upcoming two-part XRX-OXY-102 trial. Management is moving after prior study results and FDA discussions, which suggests there is enough signal to keep pushing forward. For XRTX traders, that combination of regulatory engagement plus manufacturing scale-up often becomes a narrative-driven momentum setup.
But it’s not all clean. XORTX terminated a $2.5M investor relations and marketing agreement, recovered the cash, and shelved the marketing push. At the same time, XRTX is voluntarily delisting from the TSX Venture Exchange and sticking with Nasdaq only. That move tightens the capital-markets footprint and might reduce some liquidity and Canadian retail flow, even as it cuts costs.
Add in a transfer agent change and corrective disclosure of $240,000 in finder’s fees tied to the April 2026 Vectus renal anti-fibrotic asset acquisition, and you get a mixed governance picture. XORTX is cleaning up, but traders will watch closely.
Conclusion
On the chart, XRTX reflects that tug-of-war between progress and risk. Over the last few weeks, XRTX has faded from the $2.40–$2.50 range down into the high $1s, closing near $1.88 on the latest day after an intraday run as high as $2.65. The 5‑minute tape shows sharp spikes and quick fades, exactly what short-term traders look for. Range from $1.74 support up through those $2.50 pushes shows XRTX is a volatility machine when headlines hit.
Fundamentally, XORTX is still a pre-commercial biotech with negative margins and heavy cash burn, but its balance sheet has some breathing room and no long-term debt. The real story remains the XRx-026 gout program and the XRX-OXY-102 trial, backed by new Xorlo and XORLO manufacturing runs. Meanwhile, the TSXV delisting, IR contract reversal, and fee disclosure show XRTX trying to reset its governance and capital-markets approach while staying Nasdaq-focused.
For active traders, that mix of binary clinical risk, governance noise, and clear catalysts is the whole game. XRTX will not trade like a slow, steady blue chip; it will trade like a catalyst-driven micro-cap where preparation and discipline matter more than opinions. As Tim Sykes likes to say, “Trade like a sniper, not a machine gun.” As Tim Bohen, lead trainer with StocksToTrade says, “I never chase price. The best opportunities allow me to enter on my terms, not when I’m feeling pressured.”. For XRTX, that means stalking clean setups around FDA updates, trial milestones, and financing headlines—then cutting losses fast if the story shifts.
This article is for educational and research purposes only and is not investment advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.